Postmenopausal Osteoporosis

Postmenopausal osteoporosis, also called osteoporosis type I, usually develops in women after menopause. It is characterised by a sharp drop in estrogen levels. These changes lead to bone loss (decrease in bone mineral density), mostly in the trabecular (spongy) bone within the hard bone cortex. This increases the risk of bone fractures and can lead to disability or even death.

Showing all 9 results

Filter our product list:
API
Antigen / Target
Therapeutic Areas
Therapeutic Indications
1
Classes of molecule​s
Isotypes
Expiry Date
CoA
Filters Sort results
Reset Apply

Product
Batch

Antigen
Molecular Class
Drug Brand
Product Concentration
CoA
Quantity per vial
Storage Temperature
Expiry Date
Price from
RANKL
Monoclonal Antibody
Prolia®
60 mg/mL
3 mg
-80°C
11/2018
282,60 
view product
Max: 4
Min: 1
Step: 1
RANKL
Monoclonal Antibody
Prolia®
60 mg/mL
3 mg
-80°C
07/2019
282,60 
view product
Max: 10
Min: 1
Step: 1
RANKL
Monoclonal Antibody
Prolia®
60 mg/mL
3 mg
-80°C
10/2019
282,60 
view product
Max: 5
Min: 1
Step: 1
RANKL
Monoclonal Antibody
Prolia®
60 mg/mL
3 mg
-80°C
04/2020
282,60 
view product
Max: 7
Min: 1
Step: 1
RANKL
Monoclonal Antibody
Prolia®
60 mg/mL
3 mg
-80°C
09/2020
282,60 
view product
Max: 2
Min: 1
Step: 1
RANKL
Monoclonal Antibody
Prolia®
60 mg/mL
3 mg
-80°C
01/2021
282,60 
view product
Max: 2
Min: 1
Step: 1
RANKL
Monoclonal Antibody
Prolia®
60 mg/mL
3 mg
-80°C
06/2022
282,60 
view product
Max: 10
Min: 1
Step: 1
RANKL
Monoclonal Antibody
Prolia®
60 mg/mL
3 mg
-80°C
10/2022
282,60 
view product
Max: 10
Min: 1
Step: 1
PTH1
Hormone
Forsteo®
0,25 mg/mL
0,01 mg
tba
tba
203,00 
view product
Max: 50
Min: 11
Step: 1

Not looking for Postmenopausal Osteoporosis?

Search our therapeutic molecules product database